The acquisition significantly expands Repligen's cell therapy exposure and adds a high-margin recurring revenue stream. Monitor the BioLife stockholder vote and regulatory clearance timeline — any delays or conditions could pressure the stock. Repligen's full Q2 earnings on July 28 will provide further detail on organic growth trajectory and margin expansion.
Price Chart
Executive Summary
Repligen acquires BioLife Solutions for $1.5B (64% stock, 36% cash), paying $31.00/share — a 24% premium to the 90-day VWAP. The deal adds BioLife's high-margin biopreservation media franchise (CryoStor®) and expands Repligen's cell therapy exposure. Repligen also guided preliminary Q2 revenue growth of ~12% reported / 13% organic, while BioLife posted $28.5M in Q2 revenue (+21% YoY). The transaction is expected to close in Q4 2026 and be accretive to Repligen's EPS by at least $0.05 in year one and $0.25 in year two.
Key Financial Metrics
Key Facts
- Total enterprise value of approximately $1.5 billion (64% Repligen common stock, 36% cash)
- BioLife stockholders receive $11.25 cash + 0.1442 shares of Repligen common stock per share, total value $31.00/share
- Implied premium of 24% to 90-day VWAP ended July 21, 2026
- Transaction expected to close in Q4 2026, subject to regulatory approvals and BioLife stockholder approval
- Expected to be accretive to Repligen's adjusted EPS by at least $0.05 in year one and $0.25 in year two
- Repligen expects at least $20M of synergies in year one and at least $30M in year two
- Repligen preliminary Q2 2026 revenue growth of ~12% reported, ~13% organic YoY
- BioLife preliminary Q2 2026 revenue of $28.5M, up 21% YoY from $23.4M
- Repligen pro forma cash and cash equivalents expected to exceed $300M post-close
Financial Impact
Total enterprise value $1.5B, representing ~19.5% of Repligen's $7.7B market cap. Accretion of $0.05 EPS in year one and $0.25 in year two, with $20M-$30M in cost synergies.
Risk Factors
- Integration risk — combining two companies with different cultures and customer bases
- Regulatory approval conditions or delays could push closing beyond Q4 2026
- BioLife stockholder vote may not pass if a superior offer emerges or if shareholders deem the premium insufficient
- Cell therapy market growth assumptions may prove optimistic, limiting expected revenue synergies
- Dilution from stock component (64% stock) — Repligen shareholders face ~19% dilution from the deal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3331162 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | S-4 | $181.69 $184.53 | ▲ +1.56% | ▲ +0.59% | $182.92 (+0.68%) |
Jul 28, 2026 9w ago | 8-K | $145.34 $181.69 | ▲ +25.01% | ▲ +21.63% | $182.92 (+25.86%) |
Jul 22, 2026 10w ago | 425 / 8-K | $140.09 $176.36 | ▲ +25.89% | ▲ +22.99% | $182.92 (+30.57%) |
Jul 22, 2026 10w ago | Press Release | $140.09 $176.36 | ▲ +25.89% | ▲ +22.99% | $182.92 (+30.57%) |
Jun 11, 2026 16w ago | Institutional Cluster | $130.59 $144.24 | ▲ +10.45% | ▲ +8.67% | $182.92 (+40.07%) |
May 5, 2026 21w ago | 8-K | $125.61 $121.13 | ▼ −3.57% | ▼ −8.52% | $182.92 (+45.63%) |
May 5, 2026 21w ago | Press Release | $125.61 $121.13 | ▼ −3.57% | ▼ −8.52% | $182.92 (+45.63%) |
Apr 22, 2026 23w ago | Press Release | $124.40 $108.52 | ▼ −12.77% | ▼ −15.93% | $182.92 (+47.04%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access